Which has higher valuation & earnings, PEN or LNTH?

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Penumbra $1.40B 8.92 $177.69M $4.07 78.11 Lantheus $1.54B 4.23 $233.56M $4.14 24.11

Is PEN or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 10.67% 10.50% 8.17% Lantheus 17.69% 28.10% 14.35%

Does the media prefer PEN or LNTH?

In the previous week, Lantheus had 10 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for Penumbra. Penumbra's average media sentiment score of 0.25 beat Lantheus' score of 0.23 indicating that Penumbra is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ITGR or PEN?

Penumbra has lower revenue, but higher earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.32 $102.81M $3.66 34.56 Penumbra $1.40B 8.92 $177.69M $4.07 78.11

Is ITGR or PEN more profitable?

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% Penumbra 10.67% 10.50% 8.17%

Does the media favor ITGR or PEN?

In the previous week, Integer had 4 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Integer and 1 mentions for Penumbra. Integer's average media sentiment score of 0.27 beat Penumbra's score of 0.25 indicating that Integer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EW or PEN?

In the previous week, Edwards Lifesciences had 12 more articles in the media than Penumbra. MarketBeat recorded 13 mentions for Edwards Lifesciences and 1 mentions for Penumbra. Edwards Lifesciences' average media sentiment score of 0.58 beat Penumbra's score of 0.25 indicating that Edwards Lifesciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IDXX or PEN?

In the previous week, IDEXX Laboratories had 2 more articles in the media than Penumbra. MarketBeat recorded 3 mentions for IDEXX Laboratories and 1 mentions for Penumbra. Penumbra's average media sentiment score of 0.25 beat IDEXX Laboratories' score of 0.00 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEXX Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, DXCM or PEN?

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.92 $836.30M $2.53 33.79 Penumbra $1.40B 8.92 $177.69M $4.07 78.11

Is DXCM or PEN more profitable?

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Penumbra 10.67% 10.50% 8.17%

Does the media prefer DXCM or PEN?

In the previous week, DexCom had 7 more articles in the media than Penumbra. MarketBeat recorded 8 mentions for DexCom and 1 mentions for Penumbra. DexCom's average media sentiment score of 0.44 beat Penumbra's score of 0.25 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Penumbra (PEN) Competitors

$317.74 -0.26 (-0.08%)

Closing price 03:59 PM Eastern

Extended Trading

$317.63 -0.11 (-0.03%)

As of 07:30 PM Eastern

Compare

PEN vs. LNTH, ITGR, EW, IDXX, and DXCM

Should you buy Penumbra stock or one of its competitors? Penumbra's main competitors and comparable companies include Lantheus (LNTH), Integer (ITGR), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Penumbra compare to Lantheus?

Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Penumbra has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Penumbra currently has a consensus price target of $367.07, indicating a potential upside of 15.46%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 8.30%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 10 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Lantheus and 1 mentions for Penumbra. Penumbra's average media sentiment score of 0.25 beat Lantheus' score of 0.23 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.11
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.11

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Penumbra's net margin of 10.67%. Lantheus' return on equity of 28.10% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	10.67%	10.50%	8.17%
Lantheus	17.69%	28.10%	14.35%

Summary

Lantheus beats Penumbra on 10 of the 16 factors compared between the two stocks.

How does Penumbra compare to Integer?

Integer (NYSE:ITGR) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Integer presently has a consensus price target of $109.86, indicating a potential downside of 13.14%. Penumbra has a consensus price target of $367.07, indicating a potential upside of 15.46%. Given Penumbra's stronger consensus rating and higher possible upside, analysts clearly believe Penumbra is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Integer had 4 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Integer and 1 mentions for Penumbra. Integer's average media sentiment score of 0.27 beat Penumbra's score of 0.25 indicating that Integer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of Integer shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Penumbra has lower revenue, but higher earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.32	$102.81M	$3.66	34.56
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.11

Integer has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Penumbra has a net margin of 10.67% compared to Integer's net margin of 6.97%. Integer's return on equity of 12.79% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Penumbra	10.67%	10.50%	8.17%

Summary

Penumbra beats Integer on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Edwards Lifesciences has a net margin of 15.43% compared to Penumbra's net margin of 10.67%. Edwards Lifesciences' return on equity of 15.68% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	15.43%	15.68%	12.05%
Penumbra	10.67%	10.50%	8.17%

Edwards Lifesciences has higher revenue and earnings than Penumbra. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	8.11	$1.07B	$1.74	49.12
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.11

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edwards Lifesciences presently has a consensus price target of $100.27, indicating a potential upside of 17.31%. Penumbra has a consensus price target of $367.07, indicating a potential upside of 15.46%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.74
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

In the previous week, Edwards Lifesciences had 12 more articles in the media than Penumbra. MarketBeat recorded 13 mentions for Edwards Lifesciences and 1 mentions for Penumbra. Edwards Lifesciences' average media sentiment score of 0.58 beat Penumbra's score of 0.25 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edwards Lifesciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Summary

Edwards Lifesciences beats Penumbra on 11 of the 16 factors compared between the two stocks.

How does Penumbra compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

IDEXX Laboratories has higher revenue and earnings than Penumbra. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	9.52	$1.06B	$14.22	36.56
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.11

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

IDEXX Laboratories has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

IDEXX Laboratories presently has a consensus price target of $747.00, suggesting a potential upside of 43.67%. Penumbra has a consensus price target of $367.07, suggesting a potential upside of 15.46%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities analysts clearly believe IDEXX Laboratories is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

IDEXX Laboratories has a net margin of 25.03% compared to Penumbra's net margin of 10.67%. IDEXX Laboratories' return on equity of 71.96% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	25.03%	71.96%	33.60%
Penumbra	10.67%	10.50%	8.17%

In the previous week, IDEXX Laboratories had 2 more articles in the media than Penumbra. MarketBeat recorded 3 mentions for IDEXX Laboratories and 1 mentions for Penumbra. Penumbra's average media sentiment score of 0.25 beat IDEXX Laboratories' score of 0.00 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEXX Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IDEXX Laboratories beats Penumbra on 12 of the 16 factors compared between the two stocks.

How does Penumbra compare to DexCom?

DexCom (NASDAQ:DXCM) and Penumbra (NYSE:PEN) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

DexCom presently has a consensus target price of $89.74, suggesting a potential upside of 4.96%. Penumbra has a consensus target price of $367.07, suggesting a potential upside of 15.46%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.92
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

97.8% of DexCom shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DexCom has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

DexCom has higher revenue and earnings than Penumbra. DexCom is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.92	$836.30M	$2.53	33.79
Penumbra	$1.40B	8.92	$177.69M	$4.07	78.11

DexCom has a net margin of 20.12% compared to Penumbra's net margin of 10.67%. DexCom's return on equity of 35.94% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Penumbra	10.67%	10.50%	8.17%

In the previous week, DexCom had 7 more articles in the media than Penumbra. MarketBeat recorded 8 mentions for DexCom and 1 mentions for Penumbra. DexCom's average media sentiment score of 0.44 beat Penumbra's score of 0.25 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

DexCom beats Penumbra on 12 of the 17 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEN vs. The Competition

Export

Metric	Penumbra	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.53B	$5.48B	$7.14B	$22.65B
Dividend Yield	N/A	1.81%	2.54%	3.73%
P/E Ratio	78.07	24.55	273.67	27.75
Price / Sales	8.92	67.76	611.82	21.41
Price / Cash	73.97	32.43	77.60	38.88
Price / Book	8.72	5.68	10.92	4.64
Net Income	$177.69M	$152.11M	$3.50B	$1.08B
7 Day Performance	-0.42%	-2.01%	-2.11%	-1.06%
1 Month Performance	-1.62%	-5.42%	-6.34%	-5.03%
1 Year Performance	25.28%	2.75%	8.81%	5.78%

Penumbra Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEN Penumbra	2.7738 of 5 stars	$317.74 -0.1%	$367.07 +15.5%	+27.5%	$12.53B	$1.40B	78.07	4,700
LNTH Lantheus	3.2308 of 5 stars	$99.74 flat	$108.11 +8.4%	+93.0%	$6.51B	$1.54B	24.09	1,193
ITGR Integer	2.2633 of 5 stars	$126.35 +0.0%	$109.86 -13.1%	+22.8%	$4.30B	$1.85B	34.52	11,000	High Trading Volume
EW Edwards Lifesciences	4.0094 of 5 stars	$86.97 +0.8%	$100.27 +15.3%	+11.4%	$49.69B	$6.07B	49.99	16,000
IDXX IDEXX Laboratories	4.4347 of 5 stars	$529.06 +1.9%	$747.00 +41.2%	-16.5%	$40.91B	$4.30B	37.21	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PEN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Competitors